296 related articles for article (PubMed ID: 19483401)
1. Angiogenesis regulated by VEGF and its receptors and its clinical application.
Shibuya M
Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401
[No Abstract] [Full Text] [Related]
2. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
3. [Anti-angiogenic drugs].
Sato Y
Nihon Rinsho; 2010 Jun; 68(6):1054-8. PubMed ID: 20535955
[TBL] [Abstract][Full Text] [Related]
4. [Antiangionic drugs in soft tissue sarcoma].
Salas S; Huynh T; Deville JL; Duffaud F
Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
[TBL] [Abstract][Full Text] [Related]
5. The role of antiangiogenesis therapy: bevacizumab and beyond.
Cortés-Funes H
Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
[TBL] [Abstract][Full Text] [Related]
6. [Angiogenesis targeting in renal carcinomas].
Pouessel D; Culine S
Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
[TBL] [Abstract][Full Text] [Related]
7. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
8. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
Brower V
J Natl Cancer Inst; 2009 Jun; 101(12):846-7. PubMed ID: 19509354
[No Abstract] [Full Text] [Related]
9. [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers].
Bennis Y; Guillet B; Curti C; Pisano P
Therapie; 2010; 65(2):95-105. PubMed ID: 20478241
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: VEGF as a therapeutic target for breast cancer.
Schneider BP; Sledge GW
Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of anticancer agents that target the VEGF pathway.
Chen HX; Cleck JN
Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
14. Targeting angiogenesis in esophagogastric adenocarcinoma.
Okines AF; Reynolds AR; Cunningham D
Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Kamba T; McDonald DM
Br J Cancer; 2007 Jun; 96(12):1788-95. PubMed ID: 17519900
[TBL] [Abstract][Full Text] [Related]
16. Major treatment improvements encourage kidney cancer researchers to seek further gains.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
[No Abstract] [Full Text] [Related]
17. Angiogenesis as a therapeutic target in urothelial carcinoma.
Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
[TBL] [Abstract][Full Text] [Related]
18. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
19. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Rini BI; Sosman JA; Motzer RJ
BJU Int; 2005 Aug; 96(3):286-90. PubMed ID: 16042715
[No Abstract] [Full Text] [Related]
20. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]